Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease

Tatsufumi Oka\textsuperscript{a}, Yusuke Sakaguchi\textsuperscript{a}, Koki Hattori, Yuta Asahina, Sachio Kajimoto, Yohei Doi\textsuperscript{a}, Jun-Ya Kaimori\textsuperscript{a}, Yoshitaka Isaka\textsuperscript{a}

BACKGROUND: Real-world evidence about mineralocorticoid receptor antagonist (MRA) use has been limited in chronic kidney disease, particularly regarding its association with hard renal outcomes.

METHODS: In this retrospective cohort study, adult chronic kidney disease outpatients referred to the department of nephrology at an academic hospital between January 2005 and December 2018 were analyzed. The main inclusion criteria were estimated glomerular filtration rate $\geq 10$ and $<60$ mL/min per 1.73 m$^2$ and follow-up $\geq 90$ days. The exposure of interest was MRA use, defined as the administration of spironolactone, eplerenone, or potassium canrenoate. The primary outcome was renal replacement therapy initiation, defined as the initiation of chronic hemodialysis, peritoneal dialysis, or kidney transplantation. A marginal structural model using inverse probability of weighting was applied to account for potential time-varying confounders.

RESULTS: Among a total of 3195 patients, the median age and estimated glomerular filtration rate at baseline were 66 years and 38.4 mL/min per 1.73 m$^2$, respectively. During follow-up (median, 5.9 years), 770 patients received MRAs, 211 died, and 478 started renal replacement therapy. In an inverse probability of weighting-weighted pooled logistic regression model, MRA use was significantly associated with a 28%-lower rate of renal replacement therapy initiation (hazard ratio, 0.72 [95% CI, 0.53–0.98]). The association between MRA use and renal replacement therapy initiation was dose-dependent ($P$ for trend $<0.01$) and consistent across patient subgroups. The incidence of hyperkalemia (>5.5 mEq/L) was somewhat higher in MRA users but not significant (hazard ratio, 1.14 [95% CI, 0.88–1.48]).

CONCLUSIONS: MRA users showed a better renal prognosis across various chronic kidney disease subgroups in a real-world chronic kidney disease population.

Preventing kidney failure with replacement therapy (KFRT) is an ultimate treatment goal for patients with chronic kidney disease (CKD).\textsuperscript{1,2} Unfortunately, the global number of patients receiving renal replacement therapy (RRT) has been increasing,\textsuperscript{3} despite guideline-recommended therapies for CKD, including the use of ACE (angiotensin-converting enzyme) inhibitors and ARB (angiotensin II receptor blockers). This may be partly because of the phenomenon of aldosterone breakthrough. In patients on long-term ACE inhibitor and ARB therapy, plasma aldosterone levels can increase, which attenuates the renoprotective effects of ACE inhibitors and ARBs.\textsuperscript{4-6} Thus, reinforcing the conventional treatment strategy for patients with CKD remains a major clinical issue.

\textsuperscript{a}Department of Inter-Organ Communication Research in Kidney Disease, Osaka University Graduate School of Medicine, 2-2-D11, Yamada-oka, Suita, Osaka 565-0871, Japan. Email kaimori@kid.med.osaka-u.ac.jp

For Sources of Funding and Disclosures, see page 688.

© 2022 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Hypertension is available at www.ahajournals.org/journal/hyp

Hypertension. 2022;79:679–689. DOI: 10.1161/HYPERTENSIONAHA.121.18360

March 2022 679
It has been suggested that mineralocorticoid receptor antagonists (MRAs) exert renoprotective effects.\textsuperscript{7, 8} Inhibition of mineralocorticoid receptor (MR) signaling attenuates glomerulosclerosis, interstitial fibrosis, and podocyte injuries by suppressing inflammation and oxidative stress in CKD model animals.\textsuperscript{9} Randomized controlled trials (RCTs) have shown an antiproteinuric effect of MRAs in CKD patients treated with ACE inhibitors or ARBs.\textsuperscript{7, 8} Furthermore, in a recent RCT of patients with type 2 diabetes, a nonsteroidal selective MRA, finerenone, reduced the risk of hard renal outcomes.\textsuperscript{10} However, this finding was limited to albuminuric patients with type 2 diabetes and mild-to-moderate renal dysfunction because of the trial population. Notably, there has been a lack of real-world evidence examining the association between MRA use and hard renal outcomes, including KFRT.

In analyzing the association between MRA use and renal outcomes in an observational study, time-varying confounding should be considered. This is because estimated glomerular filtration rate (eGFR), a potent time-varying confounder, could change after initiation of MRAs, and this change in eGFR may, in turn, affect future MRA use (Figure 1). In the presence of such a bidirectional relationship between the time-varying exposure and confounder, Cox proportional hazards models provide biased estimates.\textsuperscript{1, 2} Here, we used a marginal structural model (MSM) to examine the effect of MRA use on the risk of progression to KFRT in a real-world CKD population.
University Hospital approved the study protocol, waiving the need for informed consent given its retrospective nature (approval number: 20352).

Exposure of Interest and Study Outcomes
The exposure of interest was MRA use, which was treated as a binary time-dependent variable. In Japan, spironolactone, eplerenone, and potassium canrenoate were clinically available. As a sensitivity analysis, the dose of MRAs was also examined as described below.

The primary outcome was RRT initiation, defined as the initiation of chronic hemodialysis, peritoneal dialysis, or kidney transplantation. The secondary outcomes were the composite of death from any cause and RRT initiation, and the composite of eGFR <15 mL/min per 1.73 m² and RRT initiation. The events of RRT initiation and death were ascertained based on electronic medical records.

Patients’ Characteristics and Laboratory Measurements
Patients’ demographics and comorbidities were extracted from electronic medical records. These included age, sex, body mass index, blood pressure, and comorbidities (diabetes, congestive heart failure, coronary heart disease, valvar heart disease, peripheral artery disease, cerebral infarction, intracranial hemorrhage, and liver cirrhosis).

Laboratory and prescription data were collected using an automated data extraction system. Laboratory data included serum albumin, creatinine, sodium, potassium, chloride, CRP (C-reactive protein), hemoglobin, and urinary protein. Urinary protein was measured both semiquantitatively with a dipstick test and quantitatively using the urine protein to creatinine ratio (g/gCre). The eGFRs were calculated using the following Japanese standard formula: 194 × creatinine−1.094 × age−0.287 (if female, × 0.739). All data measured throughout the study period were used as time-dependent variables.

Prescription data included loop and thiazide diuretics, ACE inhibitors, ARBs, potassium-lowering agents, SGLT2 (sodium-glucose cotransporter 2) inhibitors, and MRAs. These data were also treated as time-dependent variables.

Statistical Analyses
Data are presented as medians and interquartile range for continuous variables and as numbers and percentages for categorical variables.

Missing values at baseline were imputed by multiple imputation by chained equations. Since covariates with missing values (body mass index, systolic blood pressure, urine protein to creatinine ratio, eGFR, hemoglobin, sodium, potassium, chloride, albumin, and CRP) were continuous variables, we performed linear regression imputation and yielded 5 imputed data sets. These data sets were analyzed separately and combined using Rubin’s rules.

Statistical tests were 2-tailed with \( P < 0.05 \) considered significant. All statistical analyses were performed using Stata/IC 14.0 software (Stata Corp, College Station, TX).

Marginal Structural Model
For the main analyses, the MSM was used to validly determine the associations between MRA use and study outcomes. The MSM creates at each time point a pseudo-population in which no time-varying confounding exists (Figure 1) and compares subjects’ hazards of outcome events as if they had continuously received the therapy, with those as if they had never received it.15–17 In the present MSM, the inverse probability weight (IPW), which is the product of the stabilized inverse probability weight and the stabilized inverse probability of censoring weight (IPCW), was estimated at each patient visit. The inverse probability of treatment weight (or IPCW) was the reciprocal of the probability of receiving MRAs (or being uncensored) predicted by a logistic regression model with baseline and time-varying covariates. The inverse probability of treatment weight (or IPCW) was then stabilized by multiplying them by the probability of receiving MRAs (or being uncensored).
predicted by another logistic regression model with baseline covariates only. The IPWs were truncated at the first and 99th percentiles. Through this MSM approach, it was assumed that MRAs were provided to patients based on their clinical conditions at the current, most recent, and baseline visits. Hazard ratios (HRs) were estimated based on IPW-weighted pooled logistic regression models, which produce estimates equivalent to those of Cox regression models. To minimize potential residual confounding from the variables already included in the IPWs, IPW-weighted models were further adjusted for baseline covariates, which were used to estimate IPWs. In these analyses, an intention-to-treat-like approach was used. This indicates that, once a patient started taking an MRA, they were assumed to remain on it until the end of the follow-up. In the secondary analysis for the composite of eGFR <15 mL/min per 1.73 m² and RRT initiation, patients with eGFR <15 mL/min per 1.73 m² at baseline were excluded.

Baseline covariates included age, sex, body mass index, systolic blood pressure, diabetes, congestive heart failure, coronary heart disease, valvular heart disease, peripheral artery disease, cerebral infarction, intracranial hemorrhage, urinary protein, hemoglobin, eGFR, sodium, potassium, chloride, albumin, CRP, MRAs (for IPCWs only), ACE inhibitors/ARBs, loop diuretics, thiazide diuretics, potassium-lowering agents, SGLT2 inhibitors, and calendar date at baseline.

Time-varying covariates included age, urinary protein, hemoglobin, eGFR, sodium, potassium, chloride, albumin, CRP, MRAs (for IPCWs only), ACE inhibitors/ARBs, loop diuretics, thiazide diuretics, potassium-lowering agents, SGLT2 inhibitors, in- or out-of-hospital setting, and lagged variables of these laboratory data, medications, and hospital setting.

Subgroup analyses were performed to evaluate the interactions between MRA use and prespecified baseline covariates: age, sex, body mass index, systolic blood pressure, diabetes, hemoglobin, sodium, potassium, albumin, CKD stage, urine protein, and ACE inhibitors/ARBs. As recommended in the previous literature, P values for interaction were computed by adding each interaction to the IPW-weighted pooled logistic regression model used in the main analysis. The IPWs were then refitted in each subgroup to estimate the HR.

Sensitivity Analyses
Some sensitivity analyses were performed using the MSM approach. First, the association between MRA use and RRT initiation was reassessed by reclassifying patients receiving MRAs for <1 year as MRA nonusers. Second, the association was also reassessed by restricting the analysis to patients without liver cirrhosis. Third, the association between the MRA dose and RRT initiation was analyzed. Multinomial logistic regression models were used to create the stabilized inverse probability of treatment weights for 3 categories of MRA doses (high dose [intravenous injection of potassium canrenenate or ≥50 mg/d of spironolactone/eplerenone] versus low dose [<50 mg/d of spironolactone/eplerenone] versus MRA nonuse). Finally, changes in eGFR over time were compared between those with and without MRAs, using an IPW-weighted mixed-effects model. Interaction terms between MRAs and time (up to a cubic term of time) were incorporated into the model.

Additional Analyses
Progression of proteinuria, defined as worsening category of semi-quantitative urinary protein, was compared between those with and without MRAs, using the MSM approach. The incidence of hyperkalemia, defined as serum potassium levels >5.5 mEq/L, was also compared. In this safety analysis, patients receiving an MRA were additionally censored at the time of its discontinuation. In addition, to assess the potential indication bias that drugs for heart failure, such as MRAs, statins, nitrates, and anticoagulants, might have been prescribed to CKD patients expected to have a favorable renal outcome, further MSM analyses were performed. The associations between the use of these drugs and RRT initiation were examined.

RESULTS
Study Population and Patients’ Characteristics
A total of 3195 outpatients with CKD were included in the analyses (Figure 2). The median baseline eGFR was 38.4 mL/min per 1.73 m² (Table S1); the prevalence of patients with eGFR of 30 to 59 (stage 3), 15 to 29 (stage 4), and 10 to 14 mL/min per 1.73 m² (stage 5) was 67%, 25%, and 8%, respectively. Forty-one percent of patients had diabetes, and 6% had heart failure. Of the 104 MRA users at baseline, 91 received spironolactone, and 13 received eplerenone. In total, 770 patients received at least one dose of MRAs during follow-up. Patients’ characteristics at MRA initiation in MRA users versus those at baseline in nonusers are shown in the Table. MRA users were older and more likely to have diabetes. MRA users had lower levels of hemoglobin, albumin, and eGFR, and a higher CRP level than nonusers. The percentage of patients receiving ACE inhibitors/ARBs or diuretic agents was higher in MRA users. For some variables, baseline data were missing in some patients, but the frequency was low (at most, 8.6% of the total patients).

Follow-Up and Study Outcomes
During a median (interquartile range) follow-up period of 5.9 (2.9–9.9) years, 1900 patients received ACE inhibitors/ARBs, 211 died (1.00 per 100 person-years), and 478 started RRT (2.26 per 100 person-years). Of 2936 patients with eGFR ≥15 mL/min per 1.73 m² at baseline, 917 reached eGFR <15 mL/min per 1.73 m². In the MSM, MRA use was significantly associated with a 28%-lower rate of RRT initiation (HR, 0.72 [95% CI, 0.53–0.98]; Figure 3, Figure S1), and a 24%-lower rate of the composite of RRT initiation and death (HR, 0.76 [95% CI, 0.59–0.99]; Figure 3). A similar association was observed when the outcome was the composite of eGFR <15 mL/min per 1.73 m² and RRT initiation (HR, 0.75 [95% CI, 0.57–0.99]).

In additional analyses, MRA use was significantly associated with a lower risk of progression of proteinuria (HR, 0.75 [95% CI, 0.59–0.95]). The incidence of hyperkalemia was somewhat higher in MRA users, but not statistically significant (HR, 1.14 [95% CI, 0.88–1.48]). When restricting the analysis to those receiving ACE inhibitors or ARBs at baseline, this association was strengthened but still not

Oka et al Mineralocorticoid Receptor Antagonist Use in CKD

682 March 2022 Hypertension. 2022;79:679–689. DOI: 10.1161/HYPERTENSIONAHA.121.18360
Oka et al. Mineralocorticoid Receptor Antagonist Use in CKD

Significant (HR, 1.45 [95% CI, 0.93–2.24]). No significant associations were observed between the use of heart failure drugs, such as statins, warfarin, direct oral anticoagulants, and nitrates, and RRT initiation.

Sensitivity Analyses

Reclassifying patients receiving MRAs for <1 year as MRA nonusers yielded a somewhat stronger association between MRA use and RRT initiation (HR, 0.58 [95% CI, 0.40–0.85]). Restricting the analysis to patients without liver cirrhosis did not change the results substantially (Table S2). Higher MRA doses were associated with more pronounced risk reductions in terms of RRT initiation (P for trend <0.01; Figure S1). A similar association was observed when MRA use was redefined as the use of spironolactone only (Figure S2). In the IPW-weighted mixed-effects model, MRA use was associated with higher eGFRs over time than no MRA use (P<0.01; Figure 4).

Exploratory Subgroup Analyses

The associations between MRA use and the risk of RRT initiation were consistent across all the prespecified subgroups (Figure 5). Significantly lower risks were observed in patients with and without diabetes, those with CKD stage 4–5, and those with overt proteinuria. Although not statistically significant (P for interaction =0.10), ACE inhibitor/ARB users showed a relatively lower risk of RRT initiation when using MRAs than ACE inhibitor/ARB nonusers.

DISCUSSION

In the present study, MRA use was associated with a lower risk of RRT initiation in a dose-dependent manner in patients with CKD. MRA use was also associated with lower risks of the composite event (RRT initiation and all-cause death) and the progression of proteinuria, than its nonuse. The effect of MRA use on the risk of RRT initiation was consistent across patient subgroups.

Whereas strong survival benefits of spironolactone were shown in hemodialysis patients in previous RCTs, the clinical evidence for the renoprotective effects of MRAs has been limited in CKD. Most previous observational studies, RCTs, and meta-analyses focused not on hard renal end points but on surrogate end points, including short-term changes in proteinuria levels and eGFRs. A recent meta-analysis addressed hard

Figure 2. Flow diagram of the study.

CKD indicates chronic kidney disease; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonists; and RRT, renal replacement therapy.
renal end points but concluded that the effect of MRAs on hard end points was uncertain.25 The FIDELIO-DKD (The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) trial recently demonstrated that finerenone reduced the risk of hard renal outcomes.10 However, this trial did not include patients without diabetes, those with advanced CKD (eGFR <25 mL/min per 1.73 m²), or those not receiving ACE inhibitors or ARBs. Therefore, the finding cannot be extrapolated to these patients. While including a more comprehensive patient population, previous observational studies did not consider time-varying confounding between MRA use and renal outcomes.26,27 Addressing these issues, we showed significant associations of MRAs with hard renal outcomes in a large, real-world CKD population. Importantly, the present data suggest the clinical benefit of MRA use across various CKD subgroups, including patients receiving MRA subtypes other than finerenone, those without diabetes, and those with severely impaired renal function, who were not included in FIDELIO-DKD.

Some underlying mechanisms are proposed for the renoprotective effect of MRAs. First, MRAs could decrease intraglomerular pressure, preventing podocyte injury, progression of albuminuria, and subsequent albuminuria-induced tubular injury.28–30 Indeed, a
A meta-analysis reported that drug-induced reduction in proteinuria predicts subsequent renoprotection. This mechanism can reasonably be assumed in the present study because our additional analysis confirmed the lower risk of the progression of proteinuria in MRA users. Second, direct MR blockade could attenuate the deleterious effect of aldosterone breakthrough on renal function. In the present subgroup analysis, the association between MRA use and the lower incidence of KFRT was stronger in ACE inhibitor/ARB users than in nonusers, although the P value for interaction was not significant. Third, cardioprotective effects of MR blockade could prevent long-term worsening renal function, the so-called cardio-renal syndrome type 2. Fourth, effective decongestion by adding MRAs could provide long-term renoprotection because overhydration was associated with CKD progression. Finally, MR blockade could directly reduce oxidative stress and inflammation in the kidney, leading to the prevention of glomerulosclerosis, tubular injury, and fibrosis. Although the present study did not focus on nonsteroidal MRAs, increasing evidence suggests that some of these renoprotective and cardioprotective effects might be enhanced by finerenone. Compared with steroidal MRAs such as spironolactone, eplerenone, and canrenoate, finerenone works as a bulkier and more passive MR antagonist, reducing the recruitment of inflammatory- and fibrosis-inducing cofactors to the MR, and it has a more balanced kidney-heart distribution.

### Figure 3. Associations between mineralocorticoid receptor antagonist (MRA) use and study outcomes.

Hazard ratios (HRs) were estimated using pooled logistic regression models, which produce estimates equivalent to those of Cox regression models. The exposure, MRA use, was entered as a time-dependent variable into the model. Model 1: Adjusted for baseline covariates (age, sex, body mass index [BMI], systolic blood pressure [BP], diabetes, congestive heart failure, coronary heart disease, valvular heart disease, peripheral artery disease, cerebral infarction, intracranial hemorrhage, urinary protein, hemoglobin, estimated glomerular filtration rate [eGFR], sodium, potassium, chloride, albumin, C-reactive protein [CRP], ACE (angiotensin-converting enzyme) inhibitors/ARBs (angiotensin II receptor blockers), loop diuretics, thiazide diuretics, potassium-lowering agents, SGLT2 (sodium-glucose cotransporter 2) inhibitors, and calendar date). Model 2: Inverse probability weights (IPW)-weighted model. Model 3: IPW-weighted model with further regression adjustment for baseline covariates (age, sex, BMI, systolic BP, diabetes, congestive heart failure, coronary heart disease, valvular heart disease, peripheral artery disease, cerebral infarction, intracranial hemorrhage, urinary protein, hemoglobin, eGFR, sodium, potassium, chloride, albumin, CRP, ACE inhibitors/ARBs, loop diuretics, thiazide diuretics, potassium-lowering agents, SGLT2 inhibitors, and calendar date), which were already included in the IPW. RRT indicates renal replacement therapy.

| PRIMARY OUTCOME | Hazard Ratio (95% CI) | P-Value |
|-----------------|-----------------------|---------|
| RRT initiation  |                       |         |
| Model 1         | 0.75 (0.57-0.98)      | 0.035   |
| Model 2         | 0.58 (0.43-0.79)      | <0.001  |
| Model 3         | 0.72 (0.53-0.98)      | 0.039   |

| SECONDARY OUTCOME | Hazard Ratio (95% CI) | P-Value |
|-------------------|-----------------------|---------|
| RRT initiation or death |                     |         |
| Model 1           | 0.87 (0.71-1.07)      | 0.196   |
| Model 2           | 0.69 (0.55-0.87)      | 0.002   |
| Model 3           | 0.76 (0.59-0.99)      | 0.046   |

| RRT initiation or eGFR <15 | Hazard Ratio (95% CI) | P-Value |
|----------------------------|-----------------------|---------|
| Model 1                    | 0.76 (0.61-0.95)      | 0.015   |
| Model 2                    | 0.63 (0.49-0.82)      | <0.001  |
| Model 3                    | 0.75 (0.57-0.99)      | 0.045   |
Although recent clinical interest in diabetic kidney disease is shifting toward nonsteroidal MRAs, including finerenone, the present results could rekindle interest in the effectiveness of the use of steroidal MRAs for preventing KFRT. In the present study, steroidal MRA use appeared to be renoprotective, consistent with FIDELIO-DKD and FIGARO-DKD (the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease), the latter of which analyzed patients with earlier stages of CKD than FIDELIO-DKD and showed similar but statistically insignificant renoprotection by finerenone. Admittedly, the present results should be interpreted carefully due to the observational nature of the study. However, it is unlikely that a selection bias due to physicians’ preference for MRA use exaggerated the present associations between MRA use and better renal outcomes. This is because this bias, if any, would have affected these associations toward the null, given the relatively poor physical status, including lower eGFR, of MRA users (Table). In addition, reclassifying short-term MRA users as nonusers yielded the somewhat stronger association between MRA use and RRT initiation than that in the primary analysis. This indicates that short-term MRA use did not enhance the observed association, and the present intention-to-treat-like analyses should have been conservative.

To the best of our knowledge, the present study is the first to show the association of MRAs with the risk of hard renal outcomes in a real-world CKD population, addressing time-varying confounding. Extensive adjustment for various potential time-varying confounders was performed using MSM. The study had a large sample size (n=3195) and a long follow-up period (median, 5.9 years). We confirmed the robustness of this association, by showing the dose-dependency of MRAs and comparing eGFRs over time between MRA users and nonusers. The present findings are clinically relevant because the observed renal benefit of MRA use was confirmed in various CKD subgroups, including patients with and without diabetes, those with advanced CKD stages, and those with overt proteinuria.

This study has some limitations. First, given the nature of the retrospective observational study, a causal relationship between MRAs and hard renal outcomes cannot be proven. Although extensive adjustment for numerous covariates was performed, subgroup analyses were included, and the dose-response relationship between MRA use and RRT initiation was shown, the possibility of residual confounding by unmeasured variables cannot be excluded. Indeed, the retrospective design led to some missing values at baseline in some patients, though not frequently, which was addressed using multiple imputation by chained equations. In addition, physicians’ preference for MRA use could have led to a selection bias in the analyses. However, this would have biased the main results toward the null. Second, the prescription data did not show whether patients actually filled their prescriptions. Third, the drug effects were not compared among MRA subtypes because of the limited number of patients receiving eplerenone or potassium canrenone. Fourth, given that the sample sizes were small in specific subgroups, the insignificant associations between MRA use and KFRT in some subgroups could merely be due to low statistical power. Fifth, our patients were carefully followed-up by nephrologists primarily based on the recommendations made by the Japanese CKD guidelines. Therefore, the present findings cannot necessarily be extrapolated to different clinical settings. Finally, the generalizability of the present results to non-Asian CKD populations is uncertain.

In summary, we examined the association between MRA use and hard renal outcomes in a large, real-world CKD population. Even after adjustment for time-varying confounding, MRA use was found to be associated with lower risks of KFRT and the composite of death and KFRT. This association was consistently observed in patients without diabetes and those with advanced CKD, who were not included in FIDELIO-DKD. The present results suggest that the clinical benefit of MRA use may extend to MRA subtypes other than finerenone. The present study spotlights MRA use by nephrologists, which can reinforce conventional treatment plans in patients with CKD not on dialysis. Well-powered RCTs could be performed in the future to determine whether MRA use decreases the risk of KFRT in various CKD subgroups, such as patients without diabetes and those with severe renal dysfunction.

**PERSPECTIVES**

Real-world evidence about MRA use has been limited in CKD, particularly with regard to its association...
with hard renal outcomes. Importantly, time-varying confounding should be considered to validly assess this association. Addressing this issue, the present study first showed that MRA use was significantly associated with a lower risk of RRT initiation in a real-world CKD population. This association was consistently observed in patients with and without diabetes, those with advanced CKD, and those with overt proteinuria, some of whom were not included in the recent FIDELIO-DKD trial which elucidated the renoprotective effect of finerenone. The present study spotlights MRA use, which can reinforce conventional treatment plans for various CKD patients not on dialysis.

**ARTICLE INFORMATION**

Received September 7, 2021; accepted December 28, 2021.

---

| Variable               | ≤ 74 years | ≥ 75 years | Adjusted Hazard Ratio (95% CI) | P for interaction |
|------------------------|------------|------------|-------------------------------|-------------------|
| Age                    |            |            | Censored                       | 0.270             |
| Sex                    | Male       | Female     | Censored                       | 0.631             |
| BMI                    | < 22.6 kg/m² (median) | ≥ 22.6 kg/m² (median) | Censored                       | 0.077             |
| Office SBP             | < 130 mmHg (median) | ≥ 130 mmHg (median) | Censored                       | 0.184             |
| DM                     | Yes        | No         | Censored                       | 0.341             |
| Hgb                    | < 12.3 g/dL (median) | ≥ 12.3 g/dL (median) | Censored                       | 0.154             |
| Serum Na               | < 140 mEq/L (median) | ≥ 140 mEq/L (median) | Censored                       | 0.358             |
| Serum K                | < 4.4 mEq/L (median) | ≥ 4.4 mEq/L (median) | Censored                       | 0.134             |
| Serum albumin          | ≤ 3.9 g/dL (median) | ≥ 3.9 g/dL (median) | Censored                       | 0.918             |
| CKD stages             | Stage 3    | Stage 4, 5 | Censored                       | 0.665             |
| Urine protein reagent strip | Negative to trace | Trace to 1+ | 1+ or greater | 0.483             |
| ACEI or ARB            | Yes        | No         | Censored                       | 0.101             |
| Overall                |            |            | Censored                       |                   |

**Figure 5.** Associations between mineralocorticoid receptor antagonist (MRA) use and renal replacement therapy (RRT) initiation in different subgroups of patients.

ACE inhibitor indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CKD, chronic kidney disease; DM, diabetes; and SBP, systolic blood pressure.
Affiliations
Department of Nephrology (T.O., K.H., Y.A., Y.D., Y.J) and Department of Inter-Organ Communication Research in Kidney Disease (Y.S., J.-Y.K.), Osaka University Graduate School of Medicine, Osaka, Japan.

Acknowledgments
We are grateful to all patients involved in the present study. T. Oka designed the study, T. Oka, Y. Sakaguchi, K. Hattori, Y. Asahina, S. Kajimoto, and Y. Doi collected the data. T. Oka and Y. Sakaguchi analyzed the data. J.-Y. Kaimori and Y. Isaka supervised the study. All authors participated in data interpretation. T. Oka drafted the article. All authors revised the article and approved the final version of the article.

Sources of Funding
None.

Disclosures
None.

REFERENCES
1. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT, El-Nahas M, Eckardt KU, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073–2081. doi: 10.1016/S0140-6736(10)60674-5.
2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Criqui MH, Ewing L, Frick MH, Gerhard-Herman M, et al. Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts).Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2231–2281. doi: 10.1093/eurheartj/hew290.
3. Lyassange T, Ninomiya T, Jha V, Neil A, Patrice HM, Okechii I, Zhao MH, Lv J, Garg AX, Knight J, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–1982. doi: 10.1016/S0140-6736(14)61601-9.
4. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetics with nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47:1956–1939. doi: 10.1007/s00125-004-1542-0.
5. Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockers and renin-angiotensin inhibitors confers organ protection. Hypertension. 2006;49:211–216. doi: 10.1161/01.HYP.29.3.2921.
6. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone blockade. Nat Clin Pract Nephrol. 2008;4:486–492. doi: 10.1038/ncpneph0575.
7. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockers or mineralocorticoid antagonists to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641–2650. doi: 10.1681/ASN.2009070737.
8. Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T; EVALUATE Study Group. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomized, placebo-controlled trial. J Hypertens. 2009;27:2641–2650. doi: 10.1093/hypertens/hpn093.
9. Barreto-Machado JP, Sørensen PS, Tarnow L, Parving HH. Aldosterone antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Am Soc Nephrol. 2016;27:2641–2650. doi: 10.1681/ASN.2015111183.
10. Schmermund A, Lameire N, Sarno M, Eichler S, Plouin P, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system blockers for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020;10:CD007004. doi: 10.1002/14651858.CD007004.pub4.
11. Yang CT, Kor CT, Hsieh YP. Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease. J Clin Med. 2018;7:E459. doi: 10.3390/jcm7110459.
12. Blankenburg M, Kovesdy CP, Felt AK, Griner RG, Gay A. Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users. BMC Nephrol. 2020;21:61. doi: 10.1186/s12882-020-01719-7.
13. Fernandez-Fernandez B, Izquierdo MC, Valiño-Rivas L, Nastou D, Sanz AB, Ortiz A, Sanchez-Niño MD. Albumin downregulates Klotho in tubular cells. Nephrol Dial Transplant. 2016;31:1712–1722. doi: 10.1093/ndt/gft436.
14. Fernandez-Fernandez B, Rivas LV, Niño OMS, Ortiz A. Albuminuria downregulation of the anti-aging factor klotho: the missing link potentially explaining the association of pathological albuminuria with premature death. Adv Ther. 2020;37:62–72. doi: 10.1007/s12325-019-1180-5.
15. Ortiz A, Ferro CJ, Balafa O, Burnier M, Eckardt K, Haffner S, Schmidlin R, Kreckes P, Kollengod D, et al. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease (EMPATH): study protocol ahead of print May 4, 2021. Nephrol Dial Transplant. 2021;36:1093–1093. doi: 10.1093/ndt/gfaa167.
16. Heesink HJ, Kresselin TF, Hoekman J, de Zeeuw D; Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium. Drug-induced reduction in...
albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol. 2015;26:2055–2064. doi: 10.1681/ASN.2014070688
32. Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 2002;106:2967–2972. doi: 10.1161/01.cir.0000039104.56479.a2
33. Fracarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003;42:1666–1673. doi: 10.1016/j.jacc.2003.05.003
34. van den Berg TN, Rongen GA, Fröhlich GM, Deinum J, Hausenloy DJ, Riksen NP. The cardioprotective effects of mineralocorticoid receptor antagonists. Pharmacol Ther. 2014;142:72–87. doi: 10.1016/j.pharmthera.2013.11.006
35. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–1539. doi: 10.1016/j.jacc.2008.07.051
36. Tsai YC, Tsai JC, Chen SC, Chiu YW, Hwang SJ, Hung CC, Chen TH, Kuo MC, Chen HC. Association of fluid overload with kidney disease progression in advanced CKD: a prospective cohort study. Am J Kidney Dis. 2014;63:68–75. doi: 10.1053/j.ajkd.2013.06.011
37. Hung SC, Kuo KL, Peng CH, Wu CH, Wang YC, Tang DC. Association of fluid retention with anemia and clinical outcomes among patients with chronic kidney disease. J Am Heart Assoc. 2015;4:e001480. doi: 10.1161/JAHA.114.001480
38. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol. 2005;16:3306–3314. doi: 10.1681/ASN.2004090804
39. Chen H, Sun F, Zhong X, Shao Y, Yoshimura A, Liu Y. Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press Res. 2013;37:557–566. doi: 10.1159/000355736
40. Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266–273. doi: 10.1016/j.ejphar.2015.11.026
41. Agarwal R, Kokholm P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152–161. doi: 10.1093/eurheartj/ehaa736
42. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolholf P, Nowack C, Schoemer P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252–2263. doi: 10.1056/nejma2110956.